News
HKMPY
43.56
NaN%
--
Berenberg Bank Keeps Their Buy Rating on Hikma Pharmaceuticals (HIK)
TipRanks · 6d ago
Weekly Report: what happened at HKMPY last week (1102-1106)?
Weekly Report · 11/09 10:27
Barclays Remains a Hold on Hikma Pharmaceuticals (HIK)
TipRanks · 11/06 07:16
Jefferies Sticks to Its Buy Rating for Hikma Pharmaceuticals (HIK)
TipRanks · 11/05 13:15
Hikma Pharmaceuticals (HIK) Receives a Buy from Deutsche Bank
TipRanks · 11/03 18:25
Weekly Report: what happened at HKMPY last week (1026-1030)?
Weekly Report · 11/02 10:26
Weekly Report: what happened at HKMPY last week (1019-1023)?
Weekly Report · 10/26 10:26
Weekly Report: what happened at HKMPY last week (1012-1016)?
Weekly Report · 10/19 10:26
Hikma Pharmaceuticals price target lowered to 1,810 GBp from 1,870 GBp at Citi
TipRanks · 10/13 19:45
Hikma Pharmaceuticals (HIK) Gets a Buy from Citi
TipRanks · 10/13 10:37
Weekly Report: what happened at HKMPY last week (1005-1009)?
Weekly Report · 10/12 10:32
Weekly Report: what happened at HKMPY last week (0928-1002)?
Weekly Report · 10/05 10:31
Weekly Report: what happened at HKMPY last week (0921-0925)?
Weekly Report · 09/28 10:26
Jefferies Reaffirms Their Buy Rating on Hikma Pharmaceuticals (HIK)
TipRanks · 09/25 14:35
Weekly Report: what happened at HKMPY last week (0914-0918)?
Weekly Report · 09/21 10:26
Weekly Report: what happened at HKMPY last week (0907-0911)?
Weekly Report · 09/14 10:32
Berenberg Bank Sticks to Its Buy Rating for Hikma Pharmaceuticals (HIK)
TipRanks · 09/11 09:35
Hikma Pharmaceuticals upgraded to Equal Weight from Underweight at Barclays
TipRanks · 09/08 08:40
Barclays upgrades Hikma Pharmaceuticals (HIK) to a Hold
TipRanks · 09/08 06:36
Weekly Report: what happened at HKMPY last week (0831-0904)?
Weekly Report · 09/07 10:25
More
Webull provides a variety of real-time HKMPY stock news. You can receive the latest news about Hikma Pharmaceuticals Plc through multiple platforms. This information may help you make smarter investment decisions.
About HKMPY
Hikma Pharmaceuticals PLC is a multinational pharmaceutical company engaged in the development, manufacturing and marketing of a broad range of generic, branded and specialty pharmaceutical products. Its pharmaceutical operations are conducted through three business segments: Injectables, Branded and Hikma Rx. It supplies hospitals across North America, Europe and the Middle East and North Africa (MENA) region with generic injectable and specialty medicines, supported by its growing global manufacturing network. It supplies branded generic and in-licensed products from its local manufacturing facilities to retail and hospital customers across the MENA region. Through Hikma Rx, it supplies oral, respiratory and other generic and specialty products to the North American market. Its manufacturing facilities in the United States (US) supply products across a broad range of therapeutic areas, including respiratory, oncology and pain management, serving customers in both the US and Canada.